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Auditory brainstem responseAbstract Objectives: This study aimed at assessing the reversibility of Brainstem Auditory
Evoked Response (BAER) abnormalities in neonates; with risk factors such as hyperbilirubinemia
or hypoxia after therapy.
Methodology: Two groups A and B consisting of 10 neonates with hyperbilirubinemia (term and
preterm) and 10 hypoxic neonates (term and preterm) respectively, had their BAER initially
recorded at an age of less than 1 month (as soon as they were discharged from the neonatal intensive
care unit), and later at the age of 6 months. Criteria for diagnosing infants with hyperbilirubinemia
or hypoxia were a serum bilirubin of >20 mg/dl and an Apgar score less than 6, respectively. A
complete medical and family history was taken from the parents. Otoscopic examination,
tympanometry, Transient evoked otoacoustic emissions (TEOAEs) were also done.
Results: All neonates (100%) had initial BAER abnormalities; thus fulﬁlling our selection
criteria. BAER after 6 months showed signiﬁcant improvements in both groups; 60% for group
A and 55% for group B.
Conclusions: Serial BAER is a useful, noninvasive tool to detect neurodevelopmental delay
secondary to neonatal hyperbilirubinemia and hypoxia.
ª 2014 Egyptian Society of Ear, Nose, Throat and Allied Sciences. Production and hosting by Elsevier
B.V. All rights reserved.1. Introduction
Signiﬁcant hearing loss is one of the most frequent congenital
diseases present at birth; it affects around 3 out of every 1000
live births and from 2 to 4 out of every 100 newborns leaving
the neonatal intensive care unit.1Children with hearing impairments are at signiﬁcant risk
for delayed speech and language and subsequently poor aca-
demic and social development; leading to a resulting burden
on the society’s costs for providing health and educational care
for these children.3,19,4,20,21
Current guidelines include hearing screening for every
newborn at no later than 1 month of age, especially for high
risk (HR) infants, who sustain higher rates of hearing loss
compared to normal infants.1 Separate protocols of neonatal
hearing screening based on ABR technology have been
recommended.
A number of methods have been evaluated to search a reli-
able and effective technique for determining auditory functionsed.
76 O.A. Sobhy et al.in the neonates. ABR has expanded the possibility of objective
testing of hearing functions. The latter is an effective and sim-
ple method that requires less co-operation of the patient and
measures the speciﬁc part of the auditory pathway. It is not
signiﬁcantly altered by the state of consciousness, drugs and
environmental factors like the sensory input to the cortex.2
Several test-related and subject-related factors can interfere
with ABR recordings. Normal variables (e.g., age, body tem-
perature) and pathological conditions (e.g., hearing loss and
neurological disorders), can substantially inﬂuence the ABR.2
However, certain conditions such as middle ear effusion,
minor hypoxic or ischemic lesions and central nervous system
(CNS) immaturity, may have a transient course and may
subside after a short period of time.4 Consequently, ABR
ﬁndings at the initial hearing screening of HR newborns may
occasionally not correspond to the ﬁnal hearing status.
Signiﬁcant improvement or complete recovery of ABR
thresholds in HR neonates treated for hyperbilirubinemia is
probably the most characteristic example of ABR
reversibility.5,6
Complete or partial restoration of ABR has been infre-
quently reported in HR infants7 and pediatric patients suffer-
ing from a variety of medical conditions, such as hypoxia/
ischemia,8 metabolic9 and neurologic diseases,10,11 sudden
idiopathic hearing loss12 and meningitis.13 The prevalence,
however, of such ﬁndings has not been investigated so far.
The pathophysiologic mechanism of reversible sensorineu-
ral hearing loss has not yet been understood. A slow and
lengthy period of CNS maturation may be responsible for
ABR improvement or restoration to normal thresholds. Dam-
aging factors with high prevalence among HR newborns can
potentially lead to a retardation of the myelination process,
expressed as immaturity or dysfunction.14,17
Regarding the previously mentioned, our study was
designed to asses such temporary ABR abnormalities in term
and preterm neonates with risk factors; in the form of hyper-
bilirubinemia or hypoxia.2. Methods and materials
This study was carried out on 20 newborn infants (40 ears)
discharged from the NICU of Al-Raml Children’s Hospital
in the time period between July 2012 and July 2013. A full
informed consent from all infants’ parents/guardians was
taken before starting the study.
Infants were classiﬁed into 2 groups according to the risk
factor;
1. Group A: Infants diagnosed with hyperbilirubinemia
(serum bilirubin levels that exceeded 20 mg/dl).
2. Group B: Hypoxic infant (Apgar score less than 6).
Selection criteria included;
1. Less than 1 month of age.
2. No gender preference.
3. Type ‘‘A’’ tympanometry.
4. Initially absent or abnormal ABR.
Hearing assessment included complete history taking from
the parents, otoscopic examination, tympanometry using226 Hz probe, TEOAEs (in infants with absent ABR wave-
forms)15 and auditory brainstem response measurement under
natural sleep.
The Biologic System Corp Navigator Pro unit was used to
do ABR measurements twice for all infants; an initial ABR
during the ﬁrst month of life and was later re-measured after
6 months to asses improvement.
For the ABR recording, patients were sleeping naturally in
a quiet electrically shielded room. Threshold determination
was carried out using 100 ls, rarefaction, broad band clicks,
presented at a rate of 21.1/s, through inserted earphones, with
a total of 2000 sweeps, with a time window of 15 ms. Electrode
montage used was an ipsilateral montage with the positive
recording electrode on the forehead, the negative recording
electrode on the ipsilateral ear, and the ground electrode on
the contralateral ear. ABR was recorded using a low pass ﬁlter
with a cut-off frequency of 3000 Hz and a high pass ﬁlter with
a cut-off frequency of 100 Hz.
A replicable waveform at 40 dBnHL within the expected
latencies was considered as a ‘‘normal’’ or ‘‘pass’’ response.
Any ABR threshold improvements, after 6 months, compared
to initial readings were considered as a recovery.
3. Results
This study was carried out on 20 newborn infants (40 ears); 10
with a total serum bilirubin (TSB) exceeding a level of 20 mg/dl
(Group A) and 10 with an Apgar score less than 6 (Group B).
Demographic characteristics (Table 1) show that of the 20
infants, 12 were males (60%) and 8 were females (40%). The
mean age (in days) of infants at the initial ABR was
20.8 ± 3.17 for group A, and 19.50 ± 5.07 for group B.
Table 2 shows ABR threshold measurements of the two
groups; initially and 6 months later. A statistically signiﬁcant
improvement in thresholds was observed. Also, ABR thresh-
old improvements were quantitatively estimated to be 60%
improvement for group A and 55% improvement for group
B (Table 3). Assessing improved measurements in a qualitative
form was also done by comparing the number of present and
absent ABR waveforms initially to those in the follow up
6 months later (Table 4). It was found that for group A, 10
ears had absent ABR waveforms whereas only 6 had absent
waveforms 6 months later. Similarly for group B, 8 ears ini-
tially had absent ABR waveforms which were later reduced
to 5 ears with absent waveforms in the follow up.
4. Discussion
The results of this study made it clear that a great part of ABR
abnormalities initially detected in infants at risk for hearing
loss has a reversible behavior.
Fulﬁlling our prerequisites, all 10 infants (20 ears) with
hyperbilirubinemia (100%) initially had absent or abnormal
ABRs; explained as 10 ears (50%) had absent ABR waveforms
at 95 dBnHL, 5 ears (25%) showed severe hearing loss (thresh-
old above 70 dBnHL) and another 5 ears (25%) showed
moderate hearing loss (threshold of 50–60 dBnHL). Eight ears
had absent ABR waveforms together with passed TEOAEs;
suggesting an auditory neuropathy (AN) proﬁle.
On follow up 6 months later, the majority of ears 12 (60%)
displayed ABR improved thresholds. Total reversibility to
Table 1 Demographic data of the studied groups.
(n= 20) Hyperbilirubinemia (n= 20) Hypoxia (n= 20) P
No % No %
Sex
Male 12 60.0 12 60.0 v2p= 1.000
Female 8 40.0 8 40.0
Age at initial ABR
Min.–Max. 15.0–25.0 13.0–28.0
Mean ± SD 20.80 ± 3.17 19.50 ± 5.07 tp= 0.339
Median 20.50 18.50
p: P value for comparing between the two studied group.
v2: Chi square test.
t: Student t-test.
Table 2 ABR thresholds for the studied groups.
ABR thresholds Hyperbilirubinemia Hypoxia p1
Initial ABR(<1 m) (n= 10) (n= 8)
Min.–Max. 50.0–80.0 50.0–90.0 0.554
Mean ± SD 65.0 ± 12.69 68.75 ± 13.56
Median 65.0 65.0
Follow up (6m later) (n= 14) (n= 11)
Min.–Max. 40.0–90.0 40.0–60.0 0.066
Mean ± SD 57.86 ± 22.25 45.45 ± 6.88
Median 45.0 40.0
p2 0.002
* <0.001*
p1: P value for Student t-test for comparing between the two studied
groups.
p2: P value for Paired t-test for comparing between 1st and 2nd
session.
* Statistically signiﬁcant at p 6 0.05.
Table 3 Quantitative ABR threshold improvements for the studied
Hyperbilirubinemia (n=
No
ABR improvements at follow up 12
Table 4 Qualitative improvements in ABR for the studied groups.
Hyperbilirubinemia (n= 20)
No %
Initial ABR (<1 m)
Absent waveforms 10 50.0
Present waveforms 10 50.0
Follow up (6 m later)
Absent waveforms 6 30.0
Present waveforms 14 70.0
p2 0.125
p1: P value for comparing between the two studied groups.
v2: Chi square test.
FE: Fisher Exact test.
p2: P value for McNemar test for comparing between 1st and 2nd ABR
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remaining 5 ears (25%) displayed partial reversibility. Nota-
bly, 5 ears (25%) with ABR thresholds at 80 dBnHL showed
complete reversibility to normal (ABR threshold 40 dBnHL)
on re-examination. For the 8 ears with an AN proﬁle, only 2
displayed ABR improvements.
Our results are comparable to studies done by Psarommatis
et al., Sharma et al., and Agrawal et al. in that most cases but
not all showed ABR reversibility on follow up; whether partial
or complete.18–20 On the other hand, Karmer et al.21 reported
in their study that on follow-up all neonates with abnormal
ABR showed a reversion back to normal.
Time needed for the completion of the CNS maturational
processes after an injurious insult remains undetermined.
Follow-up testing some months after the initial one allows time
for increased myelination and improved general health status.
Our results consistent with many previous studies prove
this.18,19 On the other hand, an unusually extended period ofgroups.
20) Hypoxia (n= 20)
% No %
60.0 11 55.0
Hypoxia (n= 20) p1
No %
8 50.0 v2p= 1.000
8 50.0
5 31.3 FEp= 1.000
11 68.8
0.250
in right and left.
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Wong et al. found that most abnormal ABR returned to
normal at 2 years of age in a group of term babies suffering
from severe hyperbilirubinemia.
Explanation of these results may lay in that removal of bil-
irubin from the brainstem by phototherapy and/or exchange
transfusion leads to improved brain functions; thus postulating
the hypothesis of transient bilirubin toxicity or the transient
brainstem encephalopathy. Persistence of abnormalities in
auditory neuropathy cases; where from the 8 ears who had
passed TEOAEs, only 2 (25%) showed improvement while
the majority (75%) did not, may suggest permanent damage
caused by axonal degeneration and loss of myelin rather than
hair cell loss. Meanwhile, in other cases who initially had failed
TEOAEs, persistence of abnormalities could be due to either
cause; hair cell loss or axonal degeneration.
As regards the hypoxia group, all 20 ears (100%) initially
had absent or abnormal ABR; also as part of our selection
criteria. Initially, 12 ears (60%) had absent ABR waveforms
at 95 dBnHL, 4 ears (20%) showed severe hearing loss (thresh-
olds above 70 dBnHL), and another 4 ears (20%) showed
moderate hearing loss (threshold of 50–60 dBnHL).
On follow up 6 months later, most ears 11 (55%) displayed
ABR improvements; where 7 ears (35%) showed complete
reversibility to normal ABR thresholds, and 4 ears (20%)
showed partial recovery.
Our results are contradicting another study done by Misra
et al.23 on 30 term neonates with a 5-min Apgar < 6 and hyp-
oxic ischemic encephalopathy (HIE) who underwent BAER
testing with follow up at 3 months. They found that 13 out
of 30 (43.3%) neonates with birth asphyxia showed some
abnormality in ABR waveform. And on follow up 3 months
later, ABR abnormalities reverted back to normal in all the
neonates.
The reason for this discrepancy may be explained by the
fact that our study had included infants with risk factors other
than hypoxia. Infants who had no ABR reversibility were
associated with other risk factors other than hypoxia such as
kernicterus (TSB 26–29 mg/dl), NICU admission for 15–
20 days, global developmental delay, Down’s syndrome and
an infant with positive family history of hearing loss (a sister
with a cochlear implant).
Considering our results in conjunction with other results
stated in the literature, ABR has proven to be a useful, nonin-
vasive, cost effective and radiation free tool to detect the
neurodevelopmental delay secondary to hyperbilirubinemia
and hypoxia; highlighting the transient character and revers-
ibility of hearing disorders associated with the mentioned risk
factors which are obvious during the ﬁrst few months of life.
Notably, reversible ABR abnormalities were detected in a
large portion (57.7%) of the studied cases. The observed
reversibility did not only concern mild to moderate hearing
loss, but severe to profound hearing loss as well.
In conclusion, regarding clinical implications of our
research, it is not advisable to postpone hearing screening
for neonates, but postponing ampliﬁcation may be accepted.
We also recommend that the decision for early cochlear
implantation (>1 year) in high risk infants to be made cau-
tiously, and recent reliable behavioral assessment of hearing
should be obtained; given that CNS maturation changes may
be in progress. Informed consent was provided by all children’sparents/guardians. The research was approved by the ethical
committee.
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